Agarwal Nutan, Singh Smita, Kriplani Alka, Bhatla Neerja, Singh Nilanchali
Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
J Midlife Health. 2015 Jan-Mar;6(1):10-5. doi: 10.4103/0976-7800.153605.
To evaluate safety and efficacy of gabapentin in management of psychosexual symptoms in postmenopausal women.
Fifty symptomatic postmenopausal females were randomly allocated into two groups; Group I received gabapentin 900 mg/day along with calcium 500 mg and Group II was given only calcium for 6 months and followed-up at 1,3, and 6 months. Data was analyzed in terms of percentage reduction of psychosomatic and sexual symptoms. Change in lipid profile and other blood parameters by the end of study were measured.
Maximum improvement was seen in insomnia (90-98%) in gabapentin group. Improvement in anxiety was noted by 40.5, 49.5, and 53.8% at 1, 3, and 6 months, respectively, in Group I. While in Group II, maximum improvement noted was 18.6, 19.7, and 20% at 1, 3, and 6 months, respectively. Similarly for depression, improvement was 40.4,47, and 49.5%at 1, 3, and 6 months, respectively, in Group I; while it was 15.4, 16.6, and 17% at 1, 3, and 6 months, respectively, in Group II. No significant improvement in vaginal dryness and dyspareunia noted at all follow-ups in either group. Somatic symptoms reduced by 33, 36.8, and 40% at 1, 3, and 6 months, respectively, in Group I compared to 18% improvement at all follow-up in Group II. Low density lipoprotein (LDL) was raised in Group I significantly more than Group II. Other blood parameters were comparable in both groups.
Gabapentin can lead to improvement in postmenopausal psychosomatic symptoms, while sexual symptoms show no improvement. Gabapentin can lead to increase in serum LDL, hence, precaution should be taken in patients with deranged lipid profile before starting therapy and it should be monitored during course of therapy. This drug can cause minor side effects like somnolence and dizziness.
评估加巴喷丁治疗绝经后女性心理性症状的安全性和有效性。
50名有症状的绝经后女性被随机分为两组；第一组每天服用900毫克加巴喷丁以及500毫克钙，第二组仅服用钙，为期6个月，并在1、3和6个月时进行随访。对心身症状和性症状的减轻百分比进行数据分析。测量研究结束时血脂谱和其他血液参数的变化。
加巴喷丁组失眠改善最为显著（90 - 98%）。第一组在1、3和6个月时焦虑改善率分别为40.5%、49.5%和53.8%。而在第二组，1、3和6个月时最大改善率分别为18.6%、19.7%和20%。同样对于抑郁，第一组在1、3和6个月时改善率分别为40.4%、47%和49.5%；而第二组在1、3和6个月时分别为15.4%、16.6%和17%。两组在所有随访中阴道干涩和性交困难均无显著改善。第一组在1、3和6个月时躯体症状分别减轻33%、36.8%和40%，而第二组在所有随访中的改善率为18%。第一组低密度脂蛋白（LDL）升高显著高于第二组。两组其他血液参数相当。
加巴喷丁可改善绝经后心身症状，但性症状无改善。加巴喷丁可导致血清LDL升高，因此，在开始治疗前血脂异常的患者应采取预防措施，且在治疗过程中应进行监测。该药物可引起嗜睡和头晕等轻微副作用。
